Facebook
Twitter
LinkedIn
ForwardSupporting Cancer Patients with Substance Use Disorder
Many health care professionals have had limited education on supportive care topics and have learned on the job. The guidelines and literature continue to advance supportive oncology care. The Coleman Supportive Oncology Collaborative developed this set of activities to describe guideline-based care and provide ways to incorporate it into patient care.
Content was reviewed and updated 9/29/2023.
Target Audience
This activity is designed to meet the educational needs of physicians, nurses, physician assistants, and other health care professionals who care for patients with cancer.
Learning Objectives
Following this program, participants should be able to:
- Describe patient case with substance use
- Outline substance use solutions that are appropriate at beginning of treatment and during treatment
- Explain additional assessment and management approach for patients with or at risk for substance use
Sean O’Mahony, MD
Director, Section of Palliative Medicine, Department of Internal Medicine
Rush Medical College
Nicole Gastala, MD
Assistant Professor of Clinical Medicine
University of Illinois Cancer Center
Jason Tuite, LCSW, CADC
Clinical Social Worker
University of Illinois Cancer Center
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Faculty Disclosures
The faculty listed below have no relevant financial relationships with ineligible companies to disclose.
Nicole Gastala, MD
Sean O’Mahony, MD
Jason Tuite, LCSW, CADC
Planner Disclosures
The planner listed below has the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for this individual have been mitigated.
Christine B. Weldon, MBA
Eli Lilly and Company: Consulting Fee; Grant/Research Support
Genentech, Inc.: Consulting Fee; Grant/Research Support
Merck & Co., Inc.: Consulting Fee; Grant/Research Support
Pfizer Inc.: Consulting Fee; Grant/Research Support
Roche Pharmaceuticals: Consulting Fee; Grant/Research Support
None of the other planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
In support of improving patient care, this activity has been planned and implemented by the National Comprehensive Cancer Network (NCCN) and Coleman Supportive Oncology Collaborative. NCCN is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
NCCN designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
NCCN designates this educational activity for a maximum of 0.5 contact hour.
Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credit. Approval is valid until August 4, 2024. PAs should only claim credit commensurate with the extent of their participation.
Available Credit
- 0.50 AAPA Category 1 CME credit
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC contact hours
- 0.50 Participation
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing